JOHN W ABBOTT
Vehicle Board in Pittsburgh, PA
License number
Pennsylvania MV054064L
Category
Vehicle Board
Type
Vehicle Salesperson
Address
Address
Pittsburgh, PA 15238
Personal information
See more information about JOHN W ABBOTT at radaris.comName
Address
Phone
522 8Th St, New Cumberlnd, PA 17070
72 Skyline Dr, Chalfont, PA 18914
Professional information
See more information about JOHN W ABBOTT at trustoria.com
Compounds For Cardiovascular Treatment Comprising Multi-Vitamin And Anti-Platelet Aggregating Agents And Methods For Making And Using The Same
Compounds For Cardiovascular Treatment Comprising Multi-Vitamin And Anti-Platelet Aggregating Agents And Methods For Making And Using The Same
US Patent:
6274170, Aug 14, 2001
Filed:
Feb 18, 1999
Appl. No.:
9/250941
Inventors:
Richard Heibel - Hilton Head Island SC
John J. Abbott - Pittsburgh PA
John J. Abbott - Pittsburgh PA
International Classification:
A61K 958, A61K 960, A61K 962
US Classification:
424458
Abstract:
Compounds comprising multi-vitamins, zinc and an anti-platelet aggregating agent for the treatment of atherosclerotic cardiovascular disease (ASCVD) are disclosed. The compounds are provided in dosage form, and preferably include selected amounts of ascorbic acid, folic acid, vitamin E, vitamin B6 and vitamin B12. The anti-platelet aggregating agent preferably comprises aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment of ASCVD, and possess extended shelf lives.
Compounds For Prevention Of Diabetic Retinopathy
Compounds For Prevention Of Diabetic Retinopathy
US Patent:
2003009, May 29, 2003
Filed:
Nov 16, 2001
Appl. No.:
09/998574
Inventors:
Oliver Turner - Chesterfield VA, US
John Abbott - Pittsburgh PA, US
David Kinder - Elida OH, US
John Abbott - Pittsburgh PA, US
David Kinder - Elida OH, US
International Classification:
A61K033/14, A61K031/155
US Classification:
424/682000, 514/634000
Abstract:
Compounds for the prevention and retardation of diabetic retinopathy, and the loss of visual acuity and blindness that can be caused by diabetic retinopathy. The compounds may include a magnesium salt, a vasodilator, aminoguanidine, an anti-inflammatory agent, and an antioxidant.